77 Results for "

CRPC

" in MedChemExpress (MCE) Product Catalog:
Products (77)

77 Results for "CRPC" in MCE Product Catalog:

50
50 Publications Verification
Cat. No.: HY-10617A
CAS No.: 283173-50-2
Purity:  99.97%
Synonyms: AG014699; PF-01367338
Target:  

PARP

Research Areas:  

Cancer

Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .
loading...
    loading...
49
49 Cited Publications
Cat. No.: HY-10617
CAS No.: 459868-92-9
Purity:  99.56%
Synonyms: AG-014699 phosphate; PF-01367338 phosphate
Target:  

PARP

Research Areas:  

Cancer

Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .
loading...
    loading...
41
41 Cited Publications
Cat. No.: HY-102003
CAS No.: 1859053-21-6
Purity:  99.82%
Synonyms: AG014699 monocamsylate; PF-01367338 monocamsylate
Target:  

PARP

Research Areas:  

Cancer

Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-145388
CAS No.: 2380274-50-8
Purity:  99.89%
Target:  

PROTACs SWI/SNF Complex

Research Areas:  

Cancer

AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide. AU-15330 induces disease remission in castration-resistant prostate cancer (CRPC) models without toxicity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N0790
CAS No.: 545-47-1
Synonyms: Clerodol; Monogynol B; Fagarasterol
Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen receptor (AR) inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-70006
CAS No.: 851983-85-2
Synonyms: TOK-001; VN-124-1
Galeterone (TOK-001) is a potent, orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. Galeterone also functions as a CYP17 inhibitor (IC50 = 47 nM). Galeterone induces cell apoptosis. Galeterone inhibits tumor growth in human prostate cancer xenograft mouse models. Galeterone can be used for castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) research [1][2].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-137478
CAS No.: 2416873-83-9
Purity:  99.38%
Target:  

CDK

Research Areas:  

Cancer

KB-0742 is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 has potent anti-tumor activity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-124628
CAS No.: 1346564-56-4
Purity:  98.91%
Research Areas:  

Cancer

IPI-9119 is an orally active, selective and irreversible FASN inhibitor with an IC50 of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-137478A
CAS No.: 2416874-75-2
Purity:  99.24%
Target:  

CDK

Research Areas:  

Cancer

KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-135794
CAS No.: 32694-37-4
Purity:  ≥98.0%
Synonyms: 11-KDHT; 5α-Dihydro-11-keto testosterone
Target:  

Androgen Receptor

Research Areas:  

Endocrinology

11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione. 11-Ketodihydrotestosterone is an active androgen and is also a potent androgen receptor (AR) agonist with a Ki of 20.4 nM and an EC50 of 1.35 nM for human AR. 11-Ketodihydrotestosterone drives gene regulation, protein expression and cell growth in androgen-dependent prostate cancer cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10088
CAS No.: 186497-07-4
Purity:  99.37%
Synonyms: ZD4054
Research Areas:  

Endocrinology Cancer

Zibotentan (ZD4054) is a potent, selective and orally active endothelin A (ETA) receptor antagonist with a Ki of 13 nM. Zibotentan has no inhibitory effect on ETB. Zibotentan has anticancer effects and can be used for castration-resistant prostate cancer (CRPC) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-19337
CAS No.: 1297537-33-7
Synonyms: BAY 1896953; ORM-15341
Target:  

Androgen Receptor

Research Areas:  

Cancer

Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells . Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs . Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-115282A
CAS No.: 2110428-64-1
Purity:  99.22%
Synonyms: TRC-253
Target:  

Androgen Receptor

Research Areas:  

Cancer

JNJ-63576253 (TRC-253) is a potent and orally active full antagonist of androgen receptor (AR), with IC50s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the research of castration-resistant prostate cancer (CRPC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-150102
CAS No.: 2139288-26-7
Purity:  99.86%
Target:  

Androgen Receptor

Research Areas:  

Cancer

EPI-7170, a ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-19319
CAS No.: 1628316-74-4
MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC50 of 31 nM and a Kd of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors .
loading...
    loading...
Cat. No.: HY-112078
CAS No.: 1948273-02-6
Purity:  99.48%
Synonyms: VHL ligand 2; E3 ligase Ligand 1A
Target:  

Ligands for E3 Ligase

Research Areas:  

Cancer

(S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein . (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM .
loading...
    loading...
Cat. No.: HY-42424
CAS No.: 1948273-03-7
Synonyms: VHL ligand 2 hydrochloride; E3 ligase Ligand 1
Target:  

Ligands for E3 Ligase

Research Areas:  

Cancer

(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein . (S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM .
loading...
    loading...
Cat. No.: HY-P99217
CAS No.: 872514-65-3
Synonyms: AMG 102

Target:  

c-Met/HGFR

Research Areas:  

Cancer

Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
loading...
    loading...
Cat. No.: HY-109070
CAS No.: 1203490-23-6
Purity:  99.78%
Synonyms: EPI-002
Target:  

Androgen Receptor

Research Areas:  

Cancer

Ralaniten (EPI-002) is a potent and orally active antagonist of the androgen receptor-N-terminal domain (AR-NTD). Ralaniten inhibits AR transcriptional activity, with IC50 of 7.4 μM. Ralaniten can be used for the research of castration-resistant prostate cancer (CRPC) .
loading...
    loading...
Cat. No.: HY-160777
CAS No.: 1630820-51-7
Synonyms: Galeterone 3β-imidazole
Research Areas:  

Cancer

VNPP433-3β (Galeterone 3β-imidazole) is an orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. VNPP433-3β induces cell apoptosis. VNPP433-3β inhibits tumor growth in the CWR22Rv1 xenograft mouse model. VNPP433-3β can be used for the study of castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...